Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Manhattan Pharmaceuticals will continue to develop an orally delivered treatment for essential tremor, AST-915.
Subscribe to our email newsletter
The company’s decision follows positive results from Phase 1/2 clinical study of AST-915 which showed that the drug is safe and well tolerated and demonstrated a clear effect on tremor power.
The study was conducted by the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) under a CRADA agreement between the NIH and Ariston Pharmaceuticals, a wholly owned subsidiary of Manhattan Pharma.
Manhattan Pharma plans to continue to work with the NIH and to proceed toward Phase 2 with the AST-915 development program.